Pathologically complete response for unresectable stage IV rectal cancer using systemic chemotherapy with panitumumab - A case report

Japanese Journal of Cancer and Chemotherapy

Volumn 39, Issue 2, 2012, Pages 311-315

  Bamba, Takeo ^a   Suda, Takeyasu ^a   Nakano, Masato ^a   Terashima, Tetsuro ^a   Umezu, Hajime ^b  

^a NIPPON DENTAL UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

Author keywords

Complete response; Panitumumab; Rectal cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;

ADULT; ANASTOMOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CASE REPORT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; GENE MUTATION; HUMAN; MALE; PERIPHERAL NEUROPATHY; POSTOPERATIVE PERIOD; PRIMARY TUMOR; RECTUM CANCER; TREATMENT RESPONSE; UNRESECTABLE RECTUM CANCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECTAL NEOPLASMS; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84860536959     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer a randomized GERCOR study. J Clin Oncol 22(2): 229-237, 2004.
2. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncot 26(12): 2013-2019, 2008.
3. Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14): 1408-1417, 2009.
4. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27(5): 663-671, 2009.
5. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31): 4697-4705, 2010.
6. Peeters M, Price TJ, Cervantes A, et al: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28(31): 4706-4713, 2010.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17): 1757-1765, 2008.
8. Klinger M, Eipeldauer S, Hacker S, et al: Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35(5): 515-520, 2009.
9. Scappaticci FA, Fehrenbacher L, Cartwright T, et al: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91(3): 173-180, 2005.
10. Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6(10): 803-812, 2006.
11. Hartley A, Ho KF, McConkey C, et al: Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. Br J Radiol 78(934): 934-938, 2005.
12. Capirci C, Valentini V, Cionini L, et al: Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 72(1): 99-107, 2008.
13. Tan MC, Linehan DC, Hawkins WG, et al: Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 11(9): 1112-1119, 2007.
14. Bujko K, Glynne-Jones R and Bujko M: Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol 21(9): 1743-1750, 2010.